Search

Your search keyword '"Hegmann, Kurt T."' showing total 246 results
Start Over Author "Hegmann, Kurt T." Search Limiters Academic (Peer-Reviewed) Journals
246 results on '"Hegmann, Kurt T."'

1. Longitudinal parental perception of COVID-19 vaccines for children in a multi-site, cohort study

Author

Rivers, Patrick, Porter, Cynthia, LeClair, Lindsay B., Jeddy, Zuha, Fowlkes, Ashley L., Lamberte, Julie Mayo, Herder, Katherine, Smith, Madeleine, Rai, Ramona, Grant, Lauren, Hegmann, Kurt T., Jovel, Krystal, Vaughan, Molly, Mathenge, Clare, Phillips, Andrew L., Khan, Sana, Britton, Amadea, Pilishvili, Tamara, Burgess, Jefferey L., Newes-Adeyi, Gabriella, Gaglani, Manjusha, Caban-Martinez, Alberto, Yoon, Sarang, and Lutrick, Karen

Published
2024
Full Text
View/download PDF

2. Risk Factors for Reinfection with SARS-CoV-2 Omicron Variant among Previously Infected Frontline Workers

Author

Ellingson, Katherine D., Hollister, James, Porter, Cynthia J., Khan, Sana M., Feldstein, Leora R., Naleway, Allison L., Gaglani, Manjusha, Caban-Martinez, Alberto J., Tyner, Harmony L., Lowe, Ashley A., Olsho, Lauren E.W., Meece, Jennifer, Yoon, Sarang K., Mak, Josephine, Kuntz, Jennifer L., Solle, Natasha Schaefer, Respet, Karley, Baccam, Zoe, Wesley, Meredith G., Thiese, Matthew S., Yoo, Young M., Odean, Marilyn J., Miiro, Flavia N., Pickett, Steve L., Phillips, Andrew L., Grant, Lauren, Romine, James K., Herring, Meghan K., Hegmann, Kurt T., Lamberte, Julie Mayo, Sokol, Brian, Jovel, Krystal S., Thompson, Mark G., Rivers, Patrick, Pilishvili, Tamara, Lutrick, Karen, Burgess, Jefferey L., Midgley, Claire M., and Fowlkes, Ashley L.

Subjects
Diseases -- Relapse, Medical personnel -- Statistics -- Health aspects, Health
Abstract

Essential and frontline workers experience repeated occupational exposure to SARS-CoV-2 (1). The variant B.1.1.529 (Omicron) is characterized by unprecedented transmissibility and potential for immune evasion, which led to a surge [...]

Published
2023
Full Text
View/download PDF

3. Serum per- and polyfluoroalkyl substance concentrations and longitudinal change in post-infection and post-vaccination SARS-CoV-2 antibodies

Author

Hollister, James, Caban-Martinez, Alberto J., Ellingson, Katherine D., Beitel, Shawn, Fowlkes, Ashley L., Lutrick, Karen, Tyner, Harmony L., Naleway, Allison L., Yoon, Sarang K., Gaglani, Manjusha, Hunt, Danielle, Meece, Jennifer, Mayo Lamberte, Julie, Schaefer Solle, Natasha, Rose, Spencer, Dunnigan, Kayan, Khan, Sana M., Kuntz, Jennifer L., Fisher, Julia M., Coleman, Alissa, Britton, Amadea, Thiese, Matthew S., Hegmann, Kurt T., Pavuk, Marian, Ramadan, Ferris A., Fuller, Sammantha, Nematollahi, Amy, Sprissler, Ryan, and Burgess, Jefferey L.

Published
2023
Full Text
View/download PDF

4. Evaluating Immunologic and Illness Outcomes of SARS-CoV-2 Infection in Vaccinated and Unvaccinated Children Aged ≥ 5 Years, in a Multisite Longitudinal Cohort.

Author

Porter, Cynthia, Lyski, Zoe L., Uhrlaub, Jennifer L., Ellingson, Katherine D., Jeddy, Zuha, Gwynn, Lisa, Rivers, Patrick, Sprissler, Ryan, Hegmann, Kurt T., Coughlin, Melissa M., Fowlkes, Ashley L., Hollister, James, LeClair, Lindsay, Mak, Josephine, Beitel, Shawn C., Fuller, Sammantha, Zheng, Pearl Q., Vaughan, Molly, Rai, Ramona P., and Grant, Lauren

Subjects
VACCINATION of children, SARS-CoV-2 Omicron variant, VACCINATION status, DIAGNOSTIC use of polymerase chain reaction, COVID-19 vaccines, FEVER
Abstract

Simple Summary: Children with prior vaccine-induced immunity at the time of infection had more robust antibody binding against the receptor-binding domain (RBD) and S2 domain of Spike, and experienced fever less often compared to unvaccinated children during primary SARS-CoV-2 infection. Hybrid immunity, as a result of infection and vaccination to SARS-CoV-2, has been well studied in adults but limited evidence is available in children. We evaluated the antibody responses to primary SARS-CoV-2 infection among vaccinated and unvaccinated children aged ≥ 5 years. Methods: A longitudinal cohort study of children aged ≥ 5 was conducted during August 2021–August 2022, at sites in Arizona, Texas, Utah, and Florida. Children submitted weekly nasal swabs for PCR testing and provided sera 14–59 days after PCR-confirmed SARS-CoV-2 infection. Antibodies were measured by ELISA against the receptor-binding domain (RBD) and S2 domain of ancestral Spike (WA1), in addition to Omicron (BA.2) RBD, following infection in children, with and without prior monovalent ancestral mRNA COVID-19 vaccination. Results: Among the 257 participants aged 5 to 18 years, 166 (65%) had received at least two mRNA COVID-19 vaccine doses ≥ 14 days prior to infection. Of these, 53 occurred during Delta predominance, with 37 (70%) unvaccinated at the time of infection. The remaining 204 infections occurred during Omicron predominance, with 53 (26%) participants unvaccinated. After adjusting for weight, age, symptomatic infection, and gender, significantly higher mean RBD AUC values were observed among the vaccinated group compared to the unvaccinated group for both WA1 and Omicron (p < 0.0001). A smaller percentage of vaccinated children reported fever during illness, with 55 (33%) reporting fever compared to 44 (48%) unvaccinated children reporting fever (p = 0.021). Conclusions: Children with vaccine-induced immunity at the time of SARS-CoV-2 infection had higher antibody levels during convalescence and experienced less fever compared to unvaccinated children during infection. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Work-Relatedness

Author

Greaves, William W., Das, Rajiv, McKenzie, Judith Green, Sinclair, Donald C., and Hegmann, Kurt T.

Published
2018

9. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years.

Author

Feldstein, Leora R., Britton, Amadea, Grant, Lauren, Wiegand, Ryan, Ruffin, Jasmine, Babu, Tara M., Briggs Hagen, Melissa, Burgess, Jefferey L., Caban-Martinez, Alberto J., Chu, Helen Y., Ellingson, Katherine D., Englund, Janet A., Hegmann, Kurt T., Jeddy, Zuha, Lauring, Adam S., Lutrick, Karen, Martin, Emily T., Mathenge, Clare, Meece, Jennifer, and Midgley, Claire M.

Subjects
COVID-19 vaccines, VACCINE effectiveness, PROPORTIONAL hazards models, COVID-19, SARS-CoV-2
Abstract

Key Points: Question: What is the effectiveness of the bivalent COVID-19 vaccines among children and adolescents aged 5 to 17 years? Findings: In this prospective cohort study including 2959 participants aged 5 to 17 years, vaccine effectiveness against laboratory-confirmed SARS-CoV-2 infection was 54.0% and vaccine effectiveness against symptomatic COVID-19 was 49.4%. Meaning: During a period when the Omicron BA.4/5 sublineages were the predominant circulating variants, children and adolescents received protection against SARS-CoV-2 infection and symptomatic COVID-19 from the bivalent COVID-19 vaccines compared with those who were unvaccinated or received only the monovalent COVID-19 vaccine. Importance: Bivalent mRNA COVID-19 vaccines were recommended in the US for children and adolescents aged 12 years or older on September 1, 2022, and for children aged 5 to 11 years on October 12, 2022; however, data demonstrating the effectiveness of bivalent COVID-19 vaccines are limited. Objective: To assess the effectiveness of bivalent COVID-19 vaccines against SARS-CoV-2 infection and symptomatic COVID-19 among children and adolescents. Design, Setting, and Participants: Data for the period September 4, 2022, to January 31, 2023, were combined from 3 prospective US cohort studies (6 sites total) and used to estimate COVID-19 vaccine effectiveness among children and adolescents aged 5 to 17 years. A total of 2959 participants completed periodic surveys (demographics, household characteristics, chronic medical conditions, and COVID-19 symptoms) and submitted weekly self-collected nasal swabs (irrespective of symptoms); participants submitted additional nasal swabs at the onset of any symptoms. Exposure: Vaccination status was captured from the periodic surveys and supplemented with data from state immunization information systems and electronic medical records. Main Outcome and Measures: Respiratory swabs were tested for the presence of the SARS-CoV-2 virus using reverse transcriptase–polymerase chain reaction. SARS-CoV-2 infection was defined as a positive test regardless of symptoms. Symptomatic COVID-19 was defined as a positive test and 2 or more COVID-19 symptoms within 7 days of specimen collection. Cox proportional hazards models were used to estimate hazard ratios for SARS-CoV-2 infection and symptomatic COVID-19 among participants who received a bivalent COVID-19 vaccine dose vs participants who received no vaccine or monovalent vaccine doses only. Models were adjusted for age, sex, race, ethnicity, underlying health conditions, prior SARS-CoV-2 infection status, geographic site, proportion of circulating variants by site, and local virus prevalence. Results: Of the 2959 participants (47.8% were female; median age, 10.6 years [IQR, 8.0-13.2 years]; 64.6% were non-Hispanic White) included in this analysis, 25.4% received a bivalent COVID-19 vaccine dose. During the study period, 426 participants (14.4%) had laboratory-confirmed SARS-CoV-2 infection. Among these 426 participants, 184 (43.2%) had symptomatic COVID-19, 383 (89.9%) were not vaccinated or had received only monovalent COVID-19 vaccine doses (1.38 SARS-CoV-2 infections per 1000 person-days), and 43 (10.1%) had received a bivalent COVID-19 vaccine dose (0.84 SARS-CoV-2 infections per 1000 person-days). Bivalent vaccine effectiveness against SARS-CoV-2 infection was 54.0% (95% CI, 36.6%-69.1%) and vaccine effectiveness against symptomatic COVID-19 was 49.4% (95% CI, 22.2%-70.7%). The median observation time after vaccination was 276 days (IQR, 142-350 days) for participants who received only monovalent COVID-19 vaccine doses vs 50 days (IQR, 27-74 days) for those who received a bivalent COVID-19 vaccine dose. Conclusion and Relevance: The bivalent COVID-19 vaccines protected children and adolescents against SARS-CoV-2 infection and symptomatic COVID-19. These data demonstrate the benefit of COVID-19 vaccine in children and adolescents. All eligible children and adolescents should remain up to date with recommended COVID-19 vaccinations. This study uses data from 3 prospective cohort studies conducted in the US to assess vaccine effectiveness of bivalent COVID-19 vaccines against SARS-CoV-2 infection and symptomatic COVID-19 among children and adolescents. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Occupational Interstitial Lung Diseases

Author

Litow, Francesca K., Petsonk, Edward Lee, Bohnker, Bruce K., Brodkin, Carl A., Cowl, Clayton T., Guidotti, Tee L., Harber, Philip, Biggs, Jeremy J., and Hegmann, Kurt T.

Published
2015

27. Work-Related Asthma

Author

Jolly, Athena T., Klees, Julia E., Pacheco, Karin A., Guidotti, Tee L., Kipen, Howard M., Biggs, Jeremy J., Hyman, Mark H., Bohnker, Bruce K., Thiese, Matthew S., Hegmann, Kurt T., and Harber, Philip

Published
2015

33. Humoral Immune Response to Messenger RNA Coronavirus Disease 2019 Vaccination Among Children Aged 5–11 Years in a Multisite Prospective Cohort Study, September 2021–September 2022.

Author

Lyski, Zoe L, Porter, Cynthia, Uhrlaub, Jennifer L, Ellingson, Katherine D, Jeddy, Zuha, Gwynn, Lisa, Rivers, Patrick, Sprissler, Ryan, Hegmann, Kurt T, Coughlin, Melissa, Fowlkes, Ashley, Hollister, James, LeClair, Lindsay, Mak, Josephine, Beitel, Shawn C, Fuller, Sammantha, Grant, Lauren, Newes-Adeyi, Gabriella, Yoo, Young M, and Olsho, Lauren

Subjects
COVID-19, SARS-CoV-2, CORONAVIRUS diseases, VACCINATION of children, HUMORAL immunity, MESSENGER RNA
Abstract

Background The PROTECT study is a longitudinal cohort study initiated in July 2021 with weekly testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 4 states: Arizona, Florida, exas, and Utah. This study aims to examine vaccine-elicited antibody response against postvaccination SARS-CoV-2 infections. Methods Children aged 5–11 years had serum collected 14–59 days after their second dose of monovalent Pfizer-BioNTech coronavirus disease 2019 messenger RNA vaccine. Vaccine-elicited antibodies were measured using the area under the curve (AUC) and end-point titer using enzyme-linked immunosorbent assay (receptor-binding domain [RBD] and S2) and surrogate neutralization assays against ancestral (WA1) and Omicron (BA.2). Results 79 vaccinated participants (33 [41.7%] female; median age, 8.8 years [standard deviation, 1.9 years]), 48 (60.8%) were from Tucson, Arizona; 64 (81.0%) were non-Hispanic white; 63 (80.8%) attended school in person; 68 (86.1%) did not have any chronic conditions; and 47 (59.5%) were infected after vaccination. Uninfected children had higher AUCs against WA1 (P =.009) and Omicron (P =.02). The geometric mean and surrogate neutralization titer above the limit of detection was 346.0 for WA1 and 39.7 for Omicron, an 8.7-fold decrease (P <.001). After adjustment of covariates in the WA1-specific model, we observed a 47% reduction in the odds of postvaccination infection for every standard deviation increase in RBD AUC (aOR, 0.53 [95% confidence interval,.29–.97) and a 69% reduction in the odds of infection for every 3-fold increase in RBD end titer (0.31 [.06–1.57]). Conclusions Children with higher antibody levels experienced a lower incidence of postvaccination SARS-CoV-2 infection. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

44. Opioids and Safety-Sensitive Work

Author

Hegmann, Kurt T., Weiss, Michael S., Bowden, Kirk, Branco, Fernando, DuBrueler, Kimberly, Els, Charl, Harris, Jeffrey S., Mandel, Steven, McKinney, David W., Miguel, Rafael, Mueller, Kathryn L., Nadig, Robert J., Schaffer, Michael I., Studt, Larry, Talmage, James B., Travis, Russell L., Winters, Thomas, Thiese, Matthew S., and Ott, Ulrike

Published
2014

49. ACOEM Practice Guidelines : Opioids and Safety-Sensitive Work

Author

Hegmann, Kurt T., Weiss, Michael S., Bowden, Kirk, Branco, Fernando, DuBrueler, Kimberly, Els, Charl, Mandel, Steven, McKinney, David W., Miguel, Rafael, Mueller, Kathryn L., Nadig, Robert J., Schaffer, Michael I., Studt, Larry, Talmage, James B., Travis, Russell L., Winters, Thomas, Thiese, Matthew S., and Harris, Jeffrey S.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results